News

New Amendment to Digital Europe Programme Work Programme 2023-2024

Published on | 1 year ago

Programmes Digital Europe Cybersecurity Deployment: Best use of technologies

Attachments

There is 1 attachment connected to this article.

Attachments are only accessible for people with an account on the NCP Flanders website.

Sign in (if you already have an account) or sign up.

The Main Work Programme 2023-2024 for Digital Europe Programme has been amended to include new actions.

The new amendment introduces support for new initiatives:

  • Age verification application - provides means to protect under-age users from accessing content that is unsuitable/illegal to them, contributing to the implementation of the provisions on protection of minors of the Digital Services Act (DSA).
  • AI Action Summit – the third in a series of summits to be organised by France on 10 and 11 February 2025 with the aim of leveraging existing initiatives and fora involved in AI.

Besides, the text on Incident and Vulnerability Response Support and reporting has been updated to complement Member States efforts to increase the level of protection and resilience to cyber threats.

The amendments can be found in the attached document.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1728 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.